BL-8040 and Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma

计划入组 12 人 · 首次发布于 2016 年 5 月 5 日

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

计划入组 30 人 · 首次发布于 2023 年 6 月 18 日

Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

计划入组 18 人 · 首次发布于 2022 年 8 月 4 日

anti-CD1a CAR-T cell therapy (acute T-lymphoblastic leukemia/lymphoblastic lymphoma)

PA3-17

anti-BCMA CAR T-cell therapy (refractory or relapsed multiple myeloma)

CARGO Therapeutics

United States

Viridian Metals Inc

United States

Nkarta

United States

PersonGen BioTherapeutics Wins 2026 Forbes China Industry Leading Enterprise Award for Breakthrough CAR-T Innovation

FDA Approves Aucatzyl for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Valemetostat Shows Promise in Relapsed/Refractory Peripheral T-Cell Lymphoma